SRD5A3
ENSG00000128039
Target class
Enzyme
Chromosome
4
Approved drugs
1
Clinical candidates (approved and in development)
2
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Target name
- SRD5A3
- Gene name
- Steroid 5 alpha-reductase 3
- Gene symbol
- SRD5A3
- Protein name
- Polyprenal reductase (EC 1.3.1.94) (3-oxo-5-alpha-steroid 4-dehydrogenase 3) (EC 1.3.1.22) (Steroid 5-alpha-reductase 2-like) (Steroid 5-alpha-reductase 3) (S5AR 3) (SR type 3)
- FLJ13352
- SRD5A2L
- SRD5A2L1
- Gene biotype
- Protein coding
- Gene family
- Steroid 5-alpha reductase family
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 14.35
- Tissue specificity (Gini)
- 0.263
- Tissue specificity (tau)
- 0.634
- KEGG gene identifiers
- hsa:79644
- Protein interaction confidence
- 0.887633
- Protein interaction partners
- 30
- R-HSA-193048
- R-HSA-446199
- R-HSA-4755579
- End position
- 55373100
- Start position
- 55346213
- Chromosome
- 4
- Strand
- Forward
- Endoplasmic reticulum membrane
- Multi-pass membrane protein .
- Cytosol
- Plasma membrane
Publication evidence
- PubMed 20637498
- Tissue specificity (tau)
- 0.633502
- Expression inequality (Gini)
- 0.262793
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 14.35
- Brain - Spinal cord (cervical c-1)
- 12.65
- Esophagus - Mucosa
- 12.41
- Adipose - Subcutaneous
- 9.48
- Vagina
- 9.17
Expression in transcripts per million
- Cells - Cultured fibroblasts14.35
- Brain - Spinal cord (cervical c-1)12.65
- Esophagus - Mucosa12.41
- Adipose - Subcutaneous9.48
- Vagina9.17
- Breast - Mammary Tissue8.8
- Nerve - Tibial8.8
- Minor Salivary Gland8.78
- Skin - Not Sun Exposed (Suprapubic)8.77
- Skin - Sun Exposed (Lower leg)8.62
- Lung8.3
- Adipose - Visceral (Omentum)7.59
- Artery - Coronary6.67
- Adrenal Gland6.58
- Cervix - Endocervix6.26
- Thyroid6.14
- Cervix - Ectocervix5.73
- Uterus5.42
- Brain - Frontal Cortex (BA9)5.26
- Artery - Aorta5.2
- Bladder5.12
- Pancreas5.09
- Brain - Hypothalamus4.76
- Brain - Substantia nigra4.76
- Prostate4.74
And 29 more, listed on the interactive page.
- GO:0006702
- GO:0043048
- GO:0005783
- GO:0005789
- GO:0003865
- GO:0016628
- GO:0047751
- GO:0160198
Related records
Trials (184)
- "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
- 28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
- A BE Study to Compare Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg and QVAR® 40 mcg, Inhalation Aerosol
- A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade
- A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers
- A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
- A Bioequivalence Study of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) Versus Advil Dual Action Caplets (125 mg/250 mg) and Bioavailability Assessment of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) and Advil Liqui-Gels (200 mg) in Healthy Adult Subjects
- A Bioequivalence Study of Advil Tablet (Mini) (Ibuprofen 200 mg) Versus Advil Tablet (Ibuprofen 200 mg) in Healthy Adult Subjects Under Fasted Conditions and Bioavailability Assessment of Advil Tablet (Mini) Under Fed Conditions
- A Clinical Study of Curcuvail® in Patients With Non-alcoholic Fatty Liver Disease
- A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male Volunteers
- A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male Volunteers
- A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers
- A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma
- A Clinical Trial Comparing Laser TURP With and Without Dutasteride.
- A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia
- A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
- A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients
- A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors
- A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes
- A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
Drugs (2)
- Abiraterone Steroid 5-alpha-reductase inhibitor
- Dutasteride Steroid 5-alpha-reductase inhibitor